Satellos Bioscience Inc. (MSLE)Healthcare | Biotechnology | Toronto, Canada | NasdaqGM
8.70 USD
+0.11
(1.281%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.70 Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:10 p.m. EDT
MSLE is a biotechnology stock with a volatile price history and negative earnings, indicating poor financial performance. The recent price movement shows a downward trend, with the stock trading below its 50-day average. Despite some positive news, such as the $57.2M fundraising and Phase 2 trial advancements, the stock's fundamentals remain weak. The short-term forecasting model shows minimal predicted price movement, suggesting limited momentum. Long-term investors should be cautious due to the company's negative earnings and lack of dividend history. The stock is not suitable for short-term trading due to its low volatility and lack of clear momentum. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.271531 |
| AutoETS | 0.278147 |
| AutoARIMA | 0.282257 |
| AutoTheta | 0.289056 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 275.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.095 |
| Excess Kurtosis | -1.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 181,903,952 |
| Forward P/E | -2.61 |
| Beta | 1.08 |
| Website | https://satellos.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5561594 |
| Address1 | Royal Bank Plaza |
| Address2 | Suite 2800 South Tower 200 Bay Street |
| All Time High | 208.08 |
| All Time Low | 0.048 |
| Ask | 9.06 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 74,230 |
| Average Daily Volume3 Month | 79,868 |
| Average Volume | 79,868 |
| Average Volume10Days | 74,230 |
| Beta | 1.083 |
| Bid | 8.49 |
| Bid Size | 1 |
| Book Value | 1.797 |
| City | Toronto |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.7 |
| Current Ratio | 7.767 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 9.5 |
| Day Low | 8.2 |
| Display Name | Satellos Bioscience |
| Earnings Timestamp | 1,774,614,600 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda | -26,455,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.716 |
| Enterprise Value | 151,229,920 |
| Eps Current Year | -2.995 |
| Eps Forward | -3.33 |
| Eps Trailing Twelve Months | -1.7 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.2022 |
| Fifty Day Average Change | -0.5022001 |
| Fifty Day Average Change Percent | -0.05457392 |
| Fifty Two Week Change Percent | 55.615936 |
| Fifty Two Week High | 13.395 |
| Fifty Two Week High Change | -4.6950006 |
| Fifty Two Week High Change Percent | -0.35050395 |
| Fifty Two Week Low | 4.524 |
| Fifty Two Week Low Change | 4.1759996 |
| Fifty Two Week Low Change Percent | 0.9230768 |
| Fifty Two Week Range | 4.524 - 13.395 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,344,000,600,000 |
| Float Shares | 19,412,586 |
| Forward Eps | -3.33 |
| Forward P E | -2.6126127 |
| Free Cashflow | -14,760,875 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 18 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -1,508,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06143 |
| Held Percent Institutions | 0.06115 |
| Implied Shares Outstanding | 20,908,501 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-02-06 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,769,731,200 |
| Last Split Factor | 1:12 |
| Long Business Summary | Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada. |
| Long Name | Satellos Bioscience Inc. |
| Market | us_market |
| Market Cap | 181,903,952 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_650365067 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -24,873,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 181,272,820 |
| Number Of Analyst Opinions | 2 |
| Open | 8.74 |
| Operating Cashflow | -23,596,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.7 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 8.59 |
| Price Eps Current Year | -2.9048414 |
| Price Hint | 2 |
| Price To Book | 4.841402 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.84 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.10999966 |
| Regular Market Change Percent | 1.2805548 |
| Regular Market Day High | 9.5 |
| Regular Market Day Low | 8.2 |
| Regular Market Day Range | 8.2 - 9.5 |
| Regular Market Open | 8.74 |
| Regular Market Previous Close | 8.59 |
| Regular Market Price | 8.7 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 75,601 |
| Return On Assets | -0.40023 |
| Return On Equity | -0.66374 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 20,831,190 |
| Shares Percent Shares Out | 0.0033000002 |
| Shares Short | 68,221 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 13,184 |
| Short Name | Satellos Bioscience Inc. |
| Short Ratio | 0.56 |
| Source Interval | 15 |
| State | ON |
| Symbol | MSLE |
| Target High Price | 40.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 30.0 |
| Target Median Price | 30.0 |
| Total Cash | 27,710,000 |
| Total Cash Per Share | 1.33 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.974335 |
| Two Hundred Day Average Change | 1.7256646 |
| Two Hundred Day Average Change Percent | 0.2474307 |
| Type Disp | Equity |
| Volume | 75,601 |
| Website | https://satellos.com |
| Zip | M5J 2J1 |